300683 海特生物
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)-3.710-10.160-2.848-5.046-0.605
总资产报酬率 ROA (%)-3.118-8.390-2.348-4.256-0.519
投入资产回报率 ROIC (%)-3.487-9.445-2.617-4.602-0.554

边际利润分析
销售毛利率 (%)34.24742.64142.84642.70948.465
营业利润率 (%)-36.858-43.237-11.666-23.755-0.991
息税前利润/营业总收入 (%)-39.469-44.969-13.140-26.421-2.769
净利润/营业总收入 (%)-35.425-43.481-11.367-21.293-1.147

收益指标分析
经营活动净收益/利润总额(%)92.64555.278114.20073.68633.176
价值变动净收益/利润总额(%)0.868-3.402-19.703-11.570-303.115
营业外收支净额/利润总额(%)4.7121.9515.5285.86412.800

偿债能力分析
流动比率 (X)4.3653.9823.5964.2995.072
速动比率 (X)4.0653.7143.2963.9604.650
资产负债率 (%)15.43015.80217.87916.01113.732
带息债务/全部投入资本 (%)0.5882.6291.3755.1826.808
股东权益/带息债务 (%)16,125.6043,543.1596,750.4641,756.5151,342.007
股东权益/负债合计 (%)546.091530.655455.539520.916621.573
利息保障倍数 (X)50.03651.56016.61022.2831.696

营运能力分析
应收账款周转天数 (天)50.97841.32431.91234.29341.732
存货周转天数 (天)101.666111.232109.866123.94397.300